Trial Outcomes & Findings for Spinal Anaesthesia With Chloroprocaine HCl 1% for Elective Lower Limb Procedures of Short Duration. (NCT NCT02481505)

NCT ID: NCT02481505

Last Updated: 2021-05-18

Results Overview

When Bromage score returns to 0 and sensitive perception returns to S1 To evaluate the efficacy of the three Chloroprocaine HCI 1% doses (i.e. 30 mg, 40 mg e 50 mg) in terms of time to complete regression of spinal block (i.e. end of anaesthesia) Bromage Score is comprised between 1 and 4 (1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

45 participants

Primary outcome timeframe

Up to 5 hours after regression of two dermatomers

Results posted on

2021-05-18

Participant Flow

Participant milestones

Participant milestones
Measure
3 mL Chloroprocaine HCl 1%
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Overall Study
STARTED
15
15
15
Overall Study
COMPLETED
15
15
15
Overall Study
NOT COMPLETED
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Spinal Anaesthesia With Chloroprocaine HCl 1% for Elective Lower Limb Procedures of Short Duration.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Total
n=45 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0.0 Participants
n=99 Participants
0.0 Participants
n=107 Participants
0.0 Participants
n=206 Participants
0 Participants
n=7 Participants
Age, Categorical
Between 18 and 65 years
15 Participants
n=99 Participants
15 Participants
n=107 Participants
15 Participants
n=206 Participants
45 Participants
n=7 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Age, Continuous
41.0 years
STANDARD_DEVIATION 11.7 • n=99 Participants
39.4 years
STANDARD_DEVIATION 12.5 • n=107 Participants
41.5 years
STANDARD_DEVIATION 13.9 • n=206 Participants
40.6 years
STANDARD_DEVIATION 12.5 • n=7 Participants
Sex: Female, Male
Female
6 Participants
n=99 Participants
6 Participants
n=107 Participants
6 Participants
n=206 Participants
18 Participants
n=7 Participants
Sex: Female, Male
Male
9 Participants
n=99 Participants
9 Participants
n=107 Participants
9 Participants
n=206 Participants
27 Participants
n=7 Participants
Region of Enrollment
Italy
15 participants
n=99 Participants
15 participants
n=107 Participants
15 participants
n=206 Participants
45 participants
n=7 Participants

PRIMARY outcome

Timeframe: Up to 5 hours after regression of two dermatomers

When Bromage score returns to 0 and sensitive perception returns to S1 To evaluate the efficacy of the three Chloroprocaine HCI 1% doses (i.e. 30 mg, 40 mg e 50 mg) in terms of time to complete regression of spinal block (i.e. end of anaesthesia) Bromage Score is comprised between 1 and 4 (1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to Regression of Spinal Block
40.8 minutes
Standard Deviation 12.1
39.4 minutes
Standard Deviation 12.5
41.5 minutes
Standard Deviation 13.9

SECONDARY outcome

Timeframe: Up to 40 min after spinal injection

Time period from spinal injection (time 0 h) to achievement of sensory block The evolution of both sensory and motor blocks, including sensory block metameric level, will be evaluated every 2 min until readiness for surgery, every 5 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 5 min until regression of two dermatomers with respect to the maximum level of sensory block.

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)
5.4 minutes
Standard Deviation 3
6.6 minutes
Standard Deviation 3.4
4.8 minutes
Standard Deviation 2

SECONDARY outcome

Timeframe: Up to 40 min after spinal injection

Time period from spinal injection (time 0 h) to achievement of motor block

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to Onset of Motor Block
6.3 minutes
Standard Deviation 3.2
6 minutes
Standard Deviation 3.3
4.4 minutes
Standard Deviation 2.3

SECONDARY outcome

Timeframe: Up to 40 min after spinal injection

Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery, i.e. loss of Pinprick sensation and Bromage's score ≥ 2 at the required metameric level ≥ T12

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to Readiness for Surgery
8 minutes
Standard Deviation 4.1
7.9 minutes
Standard Deviation 4.7
5.3 minutes
Standard Deviation 2

SECONDARY outcome

Timeframe: Up to 1 h and 40 min after readiness for surgery

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to Regression of Spinal Block
1.761 hours
Standard Deviation 0.348
2.127 hours
Standard Deviation 0.457
2.229 hours
Standard Deviation 0.379

SECONDARY outcome

Timeframe: Up to 5 h after regression of two dermatomers

Time period from spinal injection (time 0 h) to the time when sensitive perception has returned to S1

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to Resolution of Sensory Block to S1(Min)
1.761 hours
Standard Deviation 0.348
2.127 hours
Standard Deviation 0.457
2.195 hours
Standard Deviation 0.386

SECONDARY outcome

Timeframe: Up to 5 h after regression of two dermatomers

Time period from spinal injection (time 0 h) to the time when the Bromage score has returned to 0 (Bromage Scale comprises from 1 to 4, where 1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to Resolution of Motor Block
2.662 hours
Standard Deviation 0.789
3.361 hours
Standard Deviation 1.120
3.213 hours
Standard Deviation 0.856

SECONDARY outcome

Timeframe: Up to 5 h after regression of two dermatomers

Time period from spinal injection (time 0 h) to the time when the patient can walk unassisted

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to Unassisted Ambulation
2.662 hours
Standard Deviation 0.789
3.361 hours
Standard Deviation 1.120
3.213 hours
Standard Deviation 0.856

SECONDARY outcome

Timeframe: Up to 5 h after regression of two dermatomers

Metameric level of sensory block assessed from spinal injection (time 0 h) until regression of sensory block to S1

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Sensory Block Metameric Level
T2
0 participants
2 participants
2 participants
Sensory Block Metameric Level
T3
1 participants
0 participants
1 participants
Sensory Block Metameric Level
T4
3 participants
2 participants
1 participants
Sensory Block Metameric Level
T6
0 participants
1 participants
4 participants
Sensory Block Metameric Level
T7
1 participants
0 participants
1 participants
Sensory Block Metameric Level
T8
3 participants
3 participants
2 participants
Sensory Block Metameric Level
T10
3 participants
1 participants
3 participants
Sensory Block Metameric Level
T12
3 participants
5 participants
1 participants
Sensory Block Metameric Level
L1
1 participants
1 participants
0 participants

SECONDARY outcome

Timeframe: Up to 1 h and 40 min after readiness for surgery

Maximum metameric level of sensory block (decreased or absent sensation) achieved

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Maximum Level of Sensory Block
T7
1 participants
0 participants
1 participants
Maximum Level of Sensory Block
T8
3 participants
3 participants
2 participants
Maximum Level of Sensory Block
T10
3 participants
1 participants
3 participants
Maximum Level of Sensory Block
T12
3 participants
5 participants
1 participants
Maximum Level of Sensory Block
L1
1 participants
1 participants
0 participants
Maximum Level of Sensory Block
T2
0 participants
2 participants
2 participants
Maximum Level of Sensory Block
T3
1 participants
0 participants
1 participants
Maximum Level of Sensory Block
T4
3 participants
2 participants
1 participants
Maximum Level of Sensory Block
T6
0 participants
1 participants
4 participants

SECONDARY outcome

Timeframe: Up to 1 h and 40 min after readiness for surgery

Time period from spinal injection (Tsp; time 0 h) to the time when the maximum metameric level of sensory block is achieved (consider the time of the first of the two consecutive observations with the same level of sensory block)

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to Maximum Level of Sensory Block
0.224 minutes
Standard Deviation 0.14
0.235 minutes
Standard Deviation 0.077
0.234 minutes
Standard Deviation 0.098

SECONDARY outcome

Timeframe: Up to 5 h after regression of two dermatomers

Time period from spinal injection (time 0 h) to the time when the sensory block decrease of two dermatomers with respect to the maximum level of sensory block

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to Regression of Two Dermatomers With Respect to the Maximum Level of Sensory Block
0.687 hours
Standard Deviation 0.361
0.851 hours
Standard Deviation 0.468
0.695 hours
Standard Deviation 0.290

SECONDARY outcome

Timeframe: Expected up to 24 hrs post surgery

Time period from spinal injection (time 0 h) to the time when the criteria from discharge are met, even if according to the hospital procedures the patient is discharged at a later time

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to Eligibility for Home Discharge
3.021 hours
Standard Deviation 1.012
3.545 hours
Standard Deviation 1.281
3.530 hours
Standard Deviation 0.887

SECONDARY outcome

Timeframe: Expected up to 24 hrs post surgery

Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to First Spontaneous Urine Voiding
2.530 hours
Standard Deviation 0.761
3.361 hours
Standard Deviation 1.120
3.067 hours
Standard Deviation 0.755

SECONDARY outcome

Timeframe: Expected up to 24 hrs post surgery

Time from spinal injection (time 0 h) to first post-operative analgesia

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to First Post-operative Analgesia
8.186 hours
Standard Deviation 10.815
2.928 hours
Standard Deviation 1.228
2.988 hours
Standard Deviation 1.167

SECONDARY outcome

Timeframe: Expected up to 24 hrs post surgery

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Time to Administration of Rescue Anaesthesia or Rescue Analgesia
0.717 hours
Standard Deviation 0.397
0.315 hours
Standard Deviation 0.049
0 hours
Standard Deviation 0

SECONDARY outcome

Timeframe: at pre-dose, 5, 10, 30 and 60 min after spinal puncture

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma
5 minutes post-dose
16.127 minutes
Standard Deviation 20.108
20.411 minutes
Standard Deviation 23.037
24.887 minutes
Standard Deviation 20.340
Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma
10 minutes post-dose
41.440 minutes
Standard Deviation 31.778
38.851 minutes
Standard Deviation 25.492
75.833 minutes
Standard Deviation 67.635
Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma
30 minutes post-dose
57.459 minutes
Standard Deviation 43.773
67.180 minutes
Standard Deviation 36.899
97.647 minutes
Standard Deviation 61.704
Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma
60 minutes post-dose
47.020 minutes
Standard Deviation 41.381
53.093 minutes
Standard Deviation 31.803
78.380 minutes
Standard Deviation 48.403

SECONDARY outcome

Timeframe: at the time of first urine voiding post surgery

Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Excretion of 2-chloro-4-aminobenzoic Acid (CABA) in Urine
1217.7 ng/mL
Standard Deviation 627.8
1827.9 ng/mL
Standard Deviation 904.1
2103.5 ng/mL
Standard Deviation 1537.5

SECONDARY outcome

Timeframe: Up to Day 6 +/- 1 after spinal puncture

All AEs occurring or worsening after the dose of IMP

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Treatment-emergent Adverse Events (TEAEs)
Procedural pain
14 participants
13 participants
13 participants
Treatment-emergent Adverse Events (TEAEs)
Injection site pain
2 participants
3 participants
3 participants
Treatment-emergent Adverse Events (TEAEs)
nausea
0 participants
1 participants
1 participants
Treatment-emergent Adverse Events (TEAEs)
diarrhea
0 participants
1 participants
0 participants
Treatment-emergent Adverse Events (TEAEs)
vomiting
0 participants
1 participants
0 participants
Treatment-emergent Adverse Events (TEAEs)
bradycardia
0 participants
1 participants
0 participants

SECONDARY outcome

Timeframe: Up to Day 6 +/- 1 after spinal puncture

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Transient Neurological Symptoms (TNS)
day 2
0 participants
0 participants
0 participants
Transient Neurological Symptoms (TNS)
day 7
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: Up to Day 6 +/- 1 after spinal puncture

Number of patients with pain at the site of injection and at the site of surgery

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Pain Assessment at the Site of Injection and at the Site of Surgery
Immediately after regression of spinal block
0 participants
0 participants
0 participants
Pain Assessment at the Site of Injection and at the Site of Surgery
discharge
0 participants
0 participants
0 participants
Pain Assessment at the Site of Injection and at the Site of Surgery
day 2
14 participants
15 participants
15 participants
Pain Assessment at the Site of Injection and at the Site of Surgery
day 7
15 participants
15 participants
15 participants

SECONDARY outcome

Timeframe: Expected up to 24 hrs post surgery

The following normal ranges Heart Rate parameters will be used: 50-90 beats/min

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Heart Rate
screening
62.2 beats/min
Standard Deviation 8.5
67.5 beats/min
Standard Deviation 11.4
70.7 beats/min
Standard Deviation 8.6
Heart Rate
baseline
63.1 beats/min
Standard Deviation 9.4
71 beats/min
Standard Deviation 14
71.7 beats/min
Standard Deviation 9.2
Heart Rate
discharge
64.9 beats/min
Standard Deviation 7
66.9 beats/min
Standard Deviation 10
67 beats/min
Standard Deviation 8

SECONDARY outcome

Timeframe: Expected up to 24 hrs post surgery

The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used: Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Blood Pressure
Systolic Blood Pressure screening
120 mmHg
Standard Deviation 12.9
126 mmHg
Standard Deviation 21.74
121.6 mmHg
Standard Deviation 9.1
Blood Pressure
Systolic Blood Pressure baseline
116.9 mmHg
Standard Deviation 10.5
127.9 mmHg
Standard Deviation 19.7
125.5 mmHg
Standard Deviation 14.1
Blood Pressure
Systolic Blood Pressure discharge
116.9 mmHg
Standard Deviation 10.9
124.7 mmHg
Standard Deviation 14.7
121.7 mmHg
Standard Deviation 8.9
Blood Pressure
Diastolic Blood Pressure screening
81.5 mmHg
Standard Deviation 12.1
78.9 mmHg
Standard Deviation 11.9
80.5 mmHg
Standard Deviation 9.9
Blood Pressure
Diastolic Blood Pressure baseline
74.5 mmHg
Standard Deviation 10.3
79.8 mmHg
Standard Deviation 10.9
79.1 mmHg
Standard Deviation 13.3
Blood Pressure
Diastolic Blood Pressure discharge
75.5 mmHg
Standard Deviation 12.2
79 mmHg
Standard Deviation 8.1
82 mmHg
Standard Deviation 9.5

SECONDARY outcome

Timeframe: Expected up to 24 hrs post surgery

The following normal ranges SpO2 parameters will be used: Peripheral Oxygen Saturation: ≥ 95%

Outcome measures

Outcome measures
Measure
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
SpO2
screening
99.7 percentage
Standard Deviation 0.96
99.13 percentage
Standard Deviation 1.25
98.53 percentage
Standard Deviation 1.36
SpO2
baseline
99.4 percentage
Standard Deviation 0.91
99.13 percentage
Standard Deviation 0.83
98.53 percentage
Standard Deviation 1.51
SpO2
discharge
99.33 percentage
Standard Deviation 0.72
99.33 percentage
Standard Deviation 0.90
99 percentage
Standard Deviation 1.07

Adverse Events

3 mL Chloroprocaine HCl 1%

Serious events: 0 serious events
Other events: 15 other events
Deaths: 0 deaths

4 mL Chloroprocaine HCl 1%

Serious events: 0 serious events
Other events: 13 other events
Deaths: 0 deaths

5 mL Chloroprocaine HCl 1%

Serious events: 0 serious events
Other events: 13 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
3 mL Chloroprocaine HCl 1%
n=15 participants at risk
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
4 mL Chloroprocaine HCl 1%
n=15 participants at risk
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
5 mL Chloroprocaine HCl 1%
n=15 participants at risk
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl) Chloroprocaine HCl 1%: Intrathecal Route
Injury, poisoning and procedural complications
Procedural pain
93.3%
14/15 • Number of events 17 • 7 days
No SAEs and No subject discontinued for AEs
86.7%
13/15 • Number of events 20 • 7 days
No SAEs and No subject discontinued for AEs
86.7%
13/15 • Number of events 17 • 7 days
No SAEs and No subject discontinued for AEs
General disorders
injection site pain
13.3%
2/15 • Number of events 2 • 7 days
No SAEs and No subject discontinued for AEs
20.0%
3/15 • Number of events 3 • 7 days
No SAEs and No subject discontinued for AEs
20.0%
3/15 • Number of events 3 • 7 days
No SAEs and No subject discontinued for AEs
Gastrointestinal disorders
nausea
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs
6.7%
1/15 • Number of events 1 • 7 days
No SAEs and No subject discontinued for AEs
6.7%
1/15 • Number of events 1 • 7 days
No SAEs and No subject discontinued for AEs
Gastrointestinal disorders
diarrhoae
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs
6.7%
1/15 • Number of events 1 • 7 days
No SAEs and No subject discontinued for AEs
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs
Gastrointestinal disorders
vomiting
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs
6.7%
1/15 • Number of events 1 • 7 days
No SAEs and No subject discontinued for AEs
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs
Cardiac disorders
bradycardia
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs
6.7%
1/15 • Number of events 1 • 7 days
No SAEs and No subject discontinued for AEs
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs

Additional Information

Elisabetta Donati Clinical Project Leader

Sintetica SA, via Penate 5 Mendrisio

Phone: +41.91.640.42.50

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place